Targeting a new immune checkpoint to enhance cancer treatment during chemotherapy
PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy
This study is looking at how blocking a certain protein can help your body fight cancer better during chemotherapy, with the hope of improving treatment for people with advanced cancers like breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10871872 on NIH RePORTER |
What this research studies
This research investigates how inhibiting a specific protein can enhance the body's natural anti-tumor response during chemotherapy. The study focuses on understanding how tumor cells suppress immune responses and aims to restore this response by blocking the interaction between tumor-secreted proteins and immune cells. By combining this approach with chemotherapy, the goal is to improve treatment outcomes for patients with various types of advanced cancers, including breast cancer. The research employs a combination of laboratory experiments and clinical trials to evaluate the effectiveness of this strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancers, such as breast, lung, melanoma, or pancreatic cancer, who are undergoing chemotherapy.
Not a fit: Patients with early-stage cancers or those not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment outcomes and reduced relapse rates for patients undergoing chemotherapy.
How similar studies have performed: Other research has shown promising results in enhancing anti-tumor responses through similar immune checkpoint inhibition strategies, indicating potential for success in this approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Ubil, Eric S — University of Alabama at Birmingham
- Study coordinator: Ubil, Eric S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.